Antiviral Drugs Market Analysis

Drug Class - (DNA Polymerase, Reverse Transcription, Protease, Neuraminidase Inhibitors)

The global antiviral drugs market is segmented and analyzed for demand and supply by drug class into DNA polymerases, reverse transcription, protease, and neuraminidase inhibitors. Out of these, reverse transcription is anticipated to hold the largest market size by the end of 2036 on the back of the growing diagnosis and treatment rate of HIV infection and the increasing efficiency of antiviral drugs on viral diseases. In 2021, about 29 million individuals who suffered from HIV received antiretroviral therapy.

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5,355.79, which grew from USD 3,515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in the upcoming years.

Our in-depth analysis of the global market includes the following segments: